News

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Biogen rises as Alzheimer’s therapy drives Q2 beat

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage clinical pipeline support.

Biogen: Strong Q2 Doesn't Change The Math On Eroding MS Portfolio

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

BofA Lowers PT on Biogen (BIIB) to $142 From $143, Keeps a Neutral Rating

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on Biogen Inc. (NASDAQ:BIIB) to $142 from $143 on August 1, keeping a Neutral ...
Nasdaq1y

Interesting BIIB Put And Call Options For May 10th - Nasdaq

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Biogen Inc. (BIIB): A Bull Case Theory

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...